Literature DB >> 12624423

The role of circulating IGF-I: lessons from human and animal models.

Shoshana Yakar1, Yiping Wu, Jennifer Setser, Clifford J Rosen.   

Abstract

Insulin-like growth factors (IGF-I and IGF-II) play a crucial role in regulating cell proliferation and differentiation. The IGFs have mitogenic and antiapoptotic effects on normal and transformed cells. These peptide growth factors are produced by virtually all tissues and act in an endocrine, autocrine, and paracrine fashion. The endocrine form of IGF-I originates mostly (75%) from the liver and IGF-binding proteins regulate its bioactivity. Compared to other peptide growth factors, the IGFs are in abundant supply in circulation. The role of this large reservoir of IGFs has been debated for many years. In the last few years substantial progress has been made in understanding the function of the endocrine IGF-I using new animal models. This review will revisit the IGF system with particular attention to the role of circulating IGF-I in growth regulation, metabolism, and cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12624423     DOI: 10.1385/ENDO:19:3:239

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  140 in total

Review 1.  Insulin resistance--mechanisms, syndromes, and implications.

Authors:  D E Moller; J S Flier
Journal:  N Engl J Med       Date:  1991-09-26       Impact factor: 91.245

Review 2.  Growth hormone therapy for protein catabolism.

Authors:  R C Jenkins; R J Ross
Journal:  QJM       Date:  1996-11

3.  Postnatal and pubertal skeletal changes contribute predominantly to the differences in peak bone density between C3H/HeJ and C57BL/6J mice.

Authors:  C Richman; S Kutilek; N Miyakoshi; A K Srivastava; W G Beamer; L R Donahue; C J Rosen; J E Wergedal; D J Baylink; S Mohan
Journal:  J Bone Miner Res       Date:  2001-02       Impact factor: 6.741

4.  A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse).

Authors:  Y Zhou; B C Xu; H G Maheshwari; L He; M Reed; M Lozykowski; S Okada; L Cataldo; K Coschigamo; T E Wagner; G Baumann; J J Kopchick
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

5.  Overexpression of the acid-labile subunit of the IGF ternary complex in transgenic mice.

Authors:  J V Silha; Y Gui; T Modric; A Suwanichkul; S K Durham; D R Powell; L J Murphy
Journal:  Endocrinology       Date:  2001-10       Impact factor: 4.736

Review 6.  IGF-independent regulation of breast cancer growth by IGF binding proteins.

Authors:  Y Oh
Journal:  Breast Cancer Res Treat       Date:  1998-02       Impact factor: 4.872

7.  Circulating levels of IGF-1 directly regulate bone growth and density.

Authors:  Shoshana Yakar; Clifford J Rosen; Wesley G Beamer; Cheryl L Ackert-Bicknell; Yiping Wu; Jun-Li Liu; Guck T Ooi; Jennifer Setser; Jan Frystyk; Yves R Boisclair; Derek LeRoith
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

Review 8.  Expression of insulin-like growth factor-I in transgenic mice.

Authors:  A J D'Ercole
Journal:  Ann N Y Acad Sci       Date:  1993-08-27       Impact factor: 5.691

9.  A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance.

Authors:  J C Brüning; M D Michael; J N Winnay; T Hayashi; D Hörsch; D Accili; L J Goodyear; C R Kahn
Journal:  Mol Cell       Date:  1998-11       Impact factor: 17.970

10.  Serum levels of insulin-like growth factor-I in operable breast cancer in relation to the main prognostic variables and their perioperative changes in relation to those of prolactin.

Authors:  S Barni; P Lissoni; F Brivio; L Fumagalli; D Merlini; M Cataldo; F Rovelli; G Tancini
Journal:  Tumori       Date:  1994-06-30
View more
  22 in total

1.  Distinct growth hormone receptor signaling modes regulate skeletal muscle development and insulin sensitivity in mice.

Authors:  Mahendra D Mavalli; Douglas J DiGirolamo; Yong Fan; Ryan C Riddle; Kenneth S Campbell; Thomas van Groen; Stuart J Frank; Mark A Sperling; Karyn A Esser; Marcas M Bamman; Thomas L Clemens
Journal:  J Clin Invest       Date:  2010-11       Impact factor: 14.808

Review 2.  Extrapituitary growth hormone.

Authors:  S Harvey
Journal:  Endocrine       Date:  2010-10-23       Impact factor: 3.633

3.  Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short stature.

Authors:  Audrey De Rocca Serra-Nédélec; Thomas Edouard; Karine Tréguer; Mylène Tajan; Toshiyuki Araki; Marie Dance; Marianne Mus; Alexandra Montagner; Maïté Tauber; Jean-Pierre Salles; Philippe Valet; Benjamin G Neel; Patrick Raynal; Armelle Yart
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-27       Impact factor: 11.205

4.  Association of Insulin-like Growth Factor-1, Bone Mass and Inflammation to Low-energy Distal Radius Fractures and Fracture Healing in Elderly Women Attending Emergency Care.

Authors:  Simona I Chisalita; Lee Ti Chong; Maciej Wajda; Lars Adolfsson; Mischa Woisetschläger; Anna Spångeus
Journal:  Orthop Surg       Date:  2017-11       Impact factor: 2.071

5.  Clinical significance of various growth factors in patients with different gastric neoplasms.

Authors:  Lidia Kędzierska; Anna Madej-Michniewicz; Natalia Marczuk; Barbara Dołęgowska; Teresa Starzyńska; Wojciech Błogowski
Journal:  Am J Transl Res       Date:  2020-01-15       Impact factor: 4.060

6.  The bone-specific expression of Runx2 oscillates during the cell cycle to support a G1-related antiproliferative function in osteoblasts.

Authors:  Mario Galindo; Jitesh Pratap; Daniel W Young; Hayk Hovhannisyan; Hee-Jeong Im; Je-Yong Choi; Jane B Lian; Janet L Stein; Gary S Stein; Andre J van Wijnen
Journal:  J Biol Chem       Date:  2005-03-21       Impact factor: 5.157

7.  Relationship between serum IGF-1 and skeletal muscle IGF-1 mRNA expression to phosphocreatine recovery after exercise in obese men with reduced GH.

Authors:  Sulaiman R Hamarneh; Caitlin A Murphy; Cynthia W Shih; Walter Frontera; Martin Torriani; Javier E Irazoqui; Hideo Makimura
Journal:  J Clin Endocrinol Metab       Date:  2014-11-06       Impact factor: 5.958

8.  Treatment of acromegaly with SS analogues: should GH and IGF-I target levels be lowered to assert a tight control of the disease?

Authors:  R Cozzi; R Attanasio; S Grottoli; G Pagani; P Loli; V Gasco; A M Pedroncelli; M Montini; E Ghigo
Journal:  J Endocrinol Invest       Date:  2004-12       Impact factor: 4.256

9.  Dietary predictors of the insulin-like growth factor system in adolescent females: results from the Dietary Intervention Study in Children (DISC).

Authors:  Jean M Kerver; Joseph C Gardiner; Joanne F Dorgan; Cliff J Rosen; Ellen M Velie
Journal:  Am J Clin Nutr       Date:  2010-01-20       Impact factor: 7.045

10.  Oestradiol and insulin-like growth factor-1 reduce cell loss after global ischaemia in middle-aged female rats.

Authors:  M L Traub; M De Butte-Smith; R S Zukin; A M Etgen
Journal:  J Neuroendocrinol       Date:  2009-10-14       Impact factor: 3.627

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.